Longevity Biotech
Longevity Biotech is focused on developing innovative therapies for neurodegenerative diseases, with an initial focus on Parkinson's Disease. The company employs two independent platforms, the Precision Neuroscience Platform and the Hybridtide™ Platform, to profile immune health and develop immune-resetting products. It collaborates with global organizations and has received funding from notable foundations and agencies such as the Michael J. Fox Foundation, the National Multiple Sclerosis Society, NIH, and NSF.
Industries
Nr. of Employees
small (1-50)
Longevity Biotech
Philadelphia, Pennsylvania, United States, North America
Patents
Peptides comprising non-natural amino acids and methods of making and using the same
US-11278595-B2
View DetailsPeptides comprising non-natural amino acids and methods of making and using the same
US-10543255-B2
View DetailsCompositions comprising glucagon analogs and methods of making and using the same
US-9790262-B2
View DetailsPeptides comprising non-natural amino acids and methods of making and using the same
US-9789164-B2
View Details
Peptides comprising non-natural amino acids and methods of making and using the same
US-11278595-B2
View DetailsPeptides comprising non-natural amino acids and methods of making and using the same
US-10543255-B2
View DetailsCompositions comprising glucagon analogs and methods of making and using the same
US-9790262-B2
View DetailsPeptides comprising non-natural amino acids and methods of making and using the same
US-9789164-B2
View DetailsProducts
Hybrid peptidomimetic platform
A synthetic peptide scaffold approach using non‑natural amino acids to produce metabolically and structurally stable peptide candidates with tunable affinity and low immunogenicity.
Peptide therapeutic candidate for Parkinson's disease (Phase I)
A peptide‑based therapeutic candidate progressed into interventional Phase Ia/b clinical testing for Parkinson's disease.
Precision neuroscience biomarker platform
Analytical and profiling workflows to evaluate immune system 'health' and identify patients with dysfunctional immune responses for stratified therapy development.
LBT-3627
LBT-3627 is a novel, potentially disease-modifying, neuroprotective agent developed by Longevity Biotech for neuroimmune conditions such as Parkinson’s Disease. It selectively targets the VPAC2 receptor and has demonstrated neuroprotective activities including reduced inflammatory microglia, increased survival of dopaminergic neurons, and improved striatal densities in preclinical models.
LBT-6030
A stabilized dual agonist (GLP-1/GIP) in development for type 2 diabetes.
Hybridtide® platform technology
A revolutionary peptide technology allowing creation of synthetic molecules with increased durability and stability relative to conventional peptides, mimicking natural peptides and small proteins with retained potency and specificity.
Hybrid peptidomimetic platform
A synthetic peptide scaffold approach using non‑natural amino acids to produce metabolically and structurally stable peptide candidates with tunable affinity and low immunogenicity.
Peptide therapeutic candidate for Parkinson's disease (Phase I)
A peptide‑based therapeutic candidate progressed into interventional Phase Ia/b clinical testing for Parkinson's disease.
Precision neuroscience biomarker platform
Analytical and profiling workflows to evaluate immune system 'health' and identify patients with dysfunctional immune responses for stratified therapy development.
LBT-3627
LBT-3627 is a novel, potentially disease-modifying, neuroprotective agent developed by Longevity Biotech for neuroimmune conditions such as Parkinson’s Disease. It selectively targets the VPAC2 receptor and has demonstrated neuroprotective activities including reduced inflammatory microglia, increased survival of dopaminergic neurons, and improved striatal densities in preclinical models.
LBT-6030
A stabilized dual agonist (GLP-1/GIP) in development for type 2 diabetes.
Hybridtide® platform technology
A revolutionary peptide technology allowing creation of synthetic molecules with increased durability and stability relative to conventional peptides, mimicking natural peptides and small proteins with retained potency and specificity.
Services
Collaborative integration of hybrid peptidomimetic scaffold technology into partner peptide development programs to improve stability, selectivity, and immunogenicity profiles.
Conduct of interventional and observational clinical studies for neurodegenerative diseases, including participant recruitment and trial coordination.
Collaborative integration of hybrid peptidomimetic scaffold technology into partner peptide development programs to improve stability, selectivity, and immunogenicity profiles.
Conduct of interventional and observational clinical studies for neurodegenerative diseases, including participant recruitment and trial coordination.
Expertise Areas
- Peptide therapeutics development
- Oral peptide formulation
- Precision neuroscience and biomarker profiling
- Neuroimmunology and immune modulation
Key Technologies
- Peptidomimetics / hybrid peptides
- Non‑natural amino acid chemistry
- Structure‑based peptide design
- Oral peptide formulation methods
News & Updates
Recognition of his achievements in original research, including his pioneering role in the study of 'foldamers'.
The company received funding support for ALS research.
The company received a Phase II SBIR grant from NSF to advance oral delivery of Hybridtide-based therapeutics.
Partnership to develop LBT-3627 for Parkinson's.
Highlighting the company's approach to Parkinson's.
Discussion of the company's unique Hybridtide platform.
Recognition of his achievements in original research, including his pioneering role in the study of 'foldamers'.
The company received funding support for ALS research.
The company received a Phase II SBIR grant from NSF to advance oral delivery of Hybridtide-based therapeutics.
Partnership to develop LBT-3627 for Parkinson's.
Highlighting the company's approach to Parkinson's.
Discussion of the company's unique Hybridtide platform.